Teleflex Incorporated (NYSE:TFX) Director Stuart A. Randle sold 2,500 shares of Teleflex stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $265.23, for a total value of $663,075.00. Following the completion of the transaction, the director now directly owns 7,921 shares of the company’s stock, valued at $2,100,886.83. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Shares of TFX traded up $1.37 during midday trading on Friday, hitting $265.88. The company’s stock had a trading volume of 285,022 shares, compared to its average volume of 375,139. Teleflex Incorporated has a one year low of $227.52 and a one year high of $288.78. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.51 and a current ratio of 2.26. The firm has a market cap of $12.11 billion, a price-to-earnings ratio of 31.65, a PEG ratio of 2.13 and a beta of 1.12.
Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, November 1st. The medical technology company reported $2.52 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.41 by $0.11. Teleflex had a return on equity of 18.04% and a net margin of 2.81%. The company had revenue of $609.70 million for the quarter, compared to analyst estimates of $609.05 million. During the same quarter last year, the company posted $2.12 EPS. The company’s revenue for the quarter was up 14.0% compared to the same quarter last year. As a group, research analysts forecast that Teleflex Incorporated will post 9.91 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 14th. Stockholders of record on Thursday, November 15th will be paid a $0.34 dividend. The ex-dividend date of this dividend is Wednesday, November 14th. This represents a $1.36 annualized dividend and a dividend yield of 0.51%. Teleflex’s payout ratio is 16.19%.
Several equities analysts have weighed in on the company. Needham & Company LLC dropped their price objective on Teleflex from $298.00 to $279.00 and set a “buy” rating for the company in a report on Friday, August 3rd. Barclays assumed coverage on Teleflex in a report on Monday, October 15th. They issued an “equal weight” rating and a $266.00 price objective for the company. ValuEngine cut Teleflex from a “buy” rating to a “hold” rating in a report on Friday, August 3rd. TheStreet cut Teleflex from a “b” rating to a “c+” rating in a report on Friday, August 3rd. Finally, Morgan Stanley dropped their price objective on Teleflex from $310.00 to $295.00 and set an “overweight” rating for the company in a report on Friday, August 3rd. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $289.38.
Several institutional investors and hedge funds have recently modified their holdings of TFX. Parallel Advisors LLC increased its stake in shares of Teleflex by 200.0% in the 2nd quarter. Parallel Advisors LLC now owns 450 shares of the medical technology company’s stock valued at $120,000 after purchasing an additional 300 shares during the last quarter. First Hawaiian Bank bought a new stake in Teleflex during the 3rd quarter worth $156,000. Qube Research & Technologies Ltd bought a new stake in Teleflex during the 2nd quarter worth $168,000. First Light Asset Management LLC bought a new stake in Teleflex during the 2nd quarter worth $210,000. Finally, Dupont Capital Management Corp grew its position in Teleflex by 80.5% during the 2nd quarter. Dupont Capital Management Corp now owns 832 shares of the medical technology company’s stock worth $223,000 after acquiring an additional 371 shares during the last quarter. Institutional investors own 89.36% of the company’s stock.
Teleflex Company Profile
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Recommended Story: What are the reasons investors use put options?
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.